Myovant Sciences Ltd Stock News

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

Shares of Myovant Sciences Ltd. gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental endometriosis drug hit its primary and secondary en

Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001)Women receiving relugolix.

Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug Application (NDA) submitted by Myovant Sciences (MYOV), fo

BASEL, Switzerland, June 22, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a.

Myovant Sciences (MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the tre

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

Companies in the news are: MYOV, ITRM, COTY, OPK

Sumitovant Biopharma Ltd. announced today that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitov

If approved, relugolix combination tablet would be the first once-daily, oral treatment for women with heavy menstrual bleeding associated with uterine fibroids in the U.S. BASEL, Switzerland, June

Sumitovant Biopharma Ltd. announced that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant fa

Myovant Sciences (MYOV), a healthcare company focused on redefining care for women and for men, today announced additional results from its Phase 3 HERO study of once-daily, oral relugolix (120 mg) in

- Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected in the.